ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-PO979

Renal Protection during Cardiopulmonary Bypass (CPB) with a Leukocyte Modulatory Device (L-MOD)

Session Information

Category: Bioengineering and Informatics

  • 101 Bioengineering and Informatics

Authors

  • Humes, H. David, University of Michigan Medical School, Ann Arbor, Michigan, United States
  • Westover, A., Innovative BioTherapies, Inc., Ann Arbor, Michigan, United States
  • Buffington, D., Innovative BioTherapies, Inc., Ann Arbor, Michigan, United States
  • Johnston, K., Innovative BioTherapies, Ann Arbor, Michigan, United States
Background

Leukocyte activation during cardiopulmonary bypass (CPB) contributes to a systemic inflammatory response that can cause organ injury and dysfunction, including the kidney. The therapeutic value of incorporating an extracorporeal leukocyte modulatory device (L-MOD) during and after CPB was investigated. Assessment of leukocyte mediated organ injury in a pre-clinical animal model was the primary outcome criteria.

Methods

Twenty-two pigs underwent a simulated cardiothoracic surgical procedure with 180 minutes of CPB and 5 hours post-operative observation. Pigs received CPB with no intervention (Group 1, n= 9), 3 hours of L-MOD therapy by incorporation of L-MOD into the CPB circuit (Group 2, n=6) or 8 hours of L-MOD therapy using a femoral veno-venous extracorporeal circuit during and after CPB (Group 3, n=7). Leukocyte counts and activation were serially measured. Hemodynamics, pulmonary parameters and urine output were monitored as indices of organ function. Serum troponin-I and urine neutrophil gelatinase-associated lipocalin (NGAL) served as biomarkers of organ injury for heart and kidney, respectively.

Results

Leukocyte activation at the end of CPB was significantly increased in Groups 1 and 2 but not Group 3. Leukocyte counts, namely neutrophils, significantly increased post-operatively in Groups 1 and 2 but not in Group 3. Systemic vascular resistance was not as reduced post CPB for the L-MOD treated pigs and at 5 hours post CPB, organ injury markers, troponin-I and NGAL, were lowest in Group 3.

Conclusion

8 hours of L-MOD therapy limited leukocyte activation and the inflammatory response to CPB which resulted in less organ injury and dysfunction, including the kidney. Continuation of L-MOD therapy into the post-operative period was required for therapeutic impact.

Funding

  • Other NIH Support